Cargando…
In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology
The treatment of brucellosis is still problematic, because of high rates of treatment failure or relapses. As the microorganism is an intracellular pathogen, treatment requires combined regimens. However, limited existing data on in vitro combinations are avaliable for Brucellae. The aim of this stu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Microbiologia
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768412/ https://www.ncbi.nlm.nih.gov/pubmed/24031207 http://dx.doi.org/10.1590/S1517-83822008000200006 |
_version_ | 1782283777372848128 |
---|---|
author | Kilic, Selcuk Dizbay, Murat Hizel, Kenan Arman, Dilek |
author_facet | Kilic, Selcuk Dizbay, Murat Hizel, Kenan Arman, Dilek |
author_sort | Kilic, Selcuk |
collection | PubMed |
description | The treatment of brucellosis is still problematic, because of high rates of treatment failure or relapses. As the microorganism is an intracellular pathogen, treatment requires combined regimens. However, limited existing data on in vitro combinations are avaliable for Brucellae. The aim of this study was to investigate the in vitro efficacy of various traditional and new antibiotic combinations against 16 Brucella melitensis strains. The combination effect of antimicrobial agents was evaluated by E-test synergy method to obtain a fractional inhibitory concentration (FIC) index. Co-Trimoxazole (SXT) and moxifloxocin (MXF) exhibited the lowest MIC, while Rifampin (RIF) had the highest MIC in the study. Combinations with RIF showed the best synergistic activity (100% of RIF-tetracycline (TET), and 87.5% of RIF-SXT). Synergistic activity was also detected at seven (43.7%) of ciprofloxocin (CIP)-SXT, four (25%) of TET-MXF, and two (12.5%) of TET-SXT combinations. The combinations that demonstrated additivity were TET-SXT, CIP-SXT and TET-MXF. Antagonism was observed only with the TET-Streptomycin (STR) combination in three strains (18.8%). Further work including randomized controlled clinical trials is required to fully evaluate the usefulness of these data. |
format | Online Article Text |
id | pubmed-3768412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Sociedade Brasileira de Microbiologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-37684122013-09-12 In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology Kilic, Selcuk Dizbay, Murat Hizel, Kenan Arman, Dilek Braz J Microbiol Medical Microbiology The treatment of brucellosis is still problematic, because of high rates of treatment failure or relapses. As the microorganism is an intracellular pathogen, treatment requires combined regimens. However, limited existing data on in vitro combinations are avaliable for Brucellae. The aim of this study was to investigate the in vitro efficacy of various traditional and new antibiotic combinations against 16 Brucella melitensis strains. The combination effect of antimicrobial agents was evaluated by E-test synergy method to obtain a fractional inhibitory concentration (FIC) index. Co-Trimoxazole (SXT) and moxifloxocin (MXF) exhibited the lowest MIC, while Rifampin (RIF) had the highest MIC in the study. Combinations with RIF showed the best synergistic activity (100% of RIF-tetracycline (TET), and 87.5% of RIF-SXT). Synergistic activity was also detected at seven (43.7%) of ciprofloxocin (CIP)-SXT, four (25%) of TET-MXF, and two (12.5%) of TET-SXT combinations. The combinations that demonstrated additivity were TET-SXT, CIP-SXT and TET-MXF. Antagonism was observed only with the TET-Streptomycin (STR) combination in three strains (18.8%). Further work including randomized controlled clinical trials is required to fully evaluate the usefulness of these data. Sociedade Brasileira de Microbiologia 2008 2008-06-01 /pmc/articles/PMC3768412/ /pubmed/24031207 http://dx.doi.org/10.1590/S1517-83822008000200006 Text en © Sociedade Brasileira de Microbiologia http://creativecommons.org/licenses/by-nc/3.0/ All the content of the journal, except where otherwise noted, is licensed under a Creative Commons License |
spellingShingle | Medical Microbiology Kilic, Selcuk Dizbay, Murat Hizel, Kenan Arman, Dilek In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology |
title | In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology |
title_full | In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology |
title_fullStr | In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology |
title_full_unstemmed | In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology |
title_short | In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology |
title_sort | in vitro synergistic activity of antibiotic combinations against brucella melitensis using e-test methodology |
topic | Medical Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768412/ https://www.ncbi.nlm.nih.gov/pubmed/24031207 http://dx.doi.org/10.1590/S1517-83822008000200006 |
work_keys_str_mv | AT kilicselcuk invitrosynergisticactivityofantibioticcombinationsagainstbrucellamelitensisusingetestmethodology AT dizbaymurat invitrosynergisticactivityofantibioticcombinationsagainstbrucellamelitensisusingetestmethodology AT hizelkenan invitrosynergisticactivityofantibioticcombinationsagainstbrucellamelitensisusingetestmethodology AT armandilek invitrosynergisticactivityofantibioticcombinationsagainstbrucellamelitensisusingetestmethodology |